Treatment with antipsychotic (AP) agents is associated with incident thromboembolic events. However, the underpinnings of this association remain unknown. We sought to evaluate the effect of AP agents—categorized by their metabolic/sedative and hyperprolactinemia adverse effect profile—on the risk of venous thromboembolic disease during long-term follow-up. SSSFT staff can use the OVID link, or you can request a copy of this article by replying to this email. Please ensure you are clear which article you are requesting.